Controlled Substances: Proposed Aggregate Production Quotas for 2007, 51214-51217 [E6-14284]
Download as PDF
<![CDATA[
51214
Federal Register / Vol. 71, No. 167 / Tuesday, August 29, 2006 / Notices
of Community Oriented Policing
Services.
(4) Affected public who will be asked
or required to respond, as well as a brief
abstract: Primary: COPS Office hiring
grantees that are selected for in-depth
monitoring of their grant
implementation and equipment grantees
that report using COPS funds to
implement a criminal intelligence
system will be required to respond. The
Monitoring Information Collections
include two types of information
collections: the Monitoring Request for
Documentation and the 28 CFR Part 23
Monitoring Kit.
(5) An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond/reply: It is estimated that 140
respondents annually will complete the
collections: 40 respondents to the
Monitoring Request for Documentation
at 3 hours per respondent; 100
respondents to the 28 CFR Part 23
Monitoring Kit at 2 hours per response.
(6) An estimate of the total public
burden (in hours) associated with the
collection: There are an estimated 320
total annual burden hours associated
with this collection.
If additional information is required
contact: Ms. Lynn Bryant, Department
Clearance Officer, United States
Department of Justice, Justice
Management Division, Policy and
Planning Staff, Patrick Henry Building,
Suite 1600, 601 D Street, NW.,
Washington, DC 20530.
Dated: August 23, 2006.
Lynn Bryant,
Department Clearance Officer, PRA,
Department of Justice.
[FR Doc. E6–14280 Filed 8–28–06; 8:45 am]
BILLING CODE 4410–AT–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[OMB Number 1117–0034]
Agency Information Collection
Activities: Proposed Collection;
Comments Requested
60-Day Notice of Information
Collection Under Review: Collection of
Laboratory Analysis Data on Drug
Samples Tested by Non-Federal (State
and Local Government) Crime
Laboratories.
jlentini on PROD1PC65 with NOTICES
ACTION:
The Department of Justice (DOJ), Drug
Enforcement Administration (DEA), has
submitted the following information
collection request to the Office of
Management and Budget (OMB) for
review and approval in accordance with
VerDate Aug<31>2005
17:07 Aug 28, 2006
Jkt 208001
the Paperwork Reduction Act of 1995.
The proposed information collection is
published to obtain comments from the
public and affected agencies. Comments
are encouraged and will be accepted for
‘‘sixty days’’ until October 30, 2006.
This process is conducted in accordance
with 5 CFR 1320.10.
If you have comments, especially on
the estimated public burden or
associated response time, suggestions,
or need a copy of the proposed
information collection instrument with
instructions or additional information,
please contact Mark W. Caverly, Chief,
Liaison and Policy Section, Office of
Diversion Control, Drug Enforcement
Administration, Washington, DC 20537.
Written comments and suggestions
from the public and affected agencies
concerning the proposed collection of
information are encouraged. Your
comments should address one or more
of the following four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
—Evaluate the accuracy of the agencies
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Enhance the quality, utility, and
clarity of the information to be
collected; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
Overview of This Information
Collection
(1) Type of Information Collection:
Extension of a currently approved
collection.
(2) Title of the Form/Collection:
Collection of Laboratory Analysis Data
on Drug Samples Tested by Non-Federal
(State and Local Government) Crime
Laboratories.
(3) Agency form number, if any, and
the applicable component of the
Department of Justice sponsoring the
collection: Form Number: none. Office
of Diversion Control, Drug Enforcement
Administration, U.S. Department of
Justice.
(4) Affected public who will be asked
or required to respond, as well as a brief
abstract: Primary: State, Local or tribal
government. Other: None. Abstract:
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
Information is needed from state and
local laboratories to provide DEA with
additional analyzed drug information
for the National Forensic Laboratory
Information System.
(5) An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond: It is estimated that there are
one hundred fifty (150) total
respondents for this information
collection. One hundred twenty (120)
respond monthly at .16 hour (10
minutes) for each response and thirty
(30) respond quarterly at .16 hour (10
minutes) for each response, for a total
number of 1560 respondents.
(6) An estimate of the total public
burden (in hours) associated with the
collection: It is estimated that there are
259 annual burden hours associated
with this collection.
If additional information is required
contact: Lynn Bryant, Department
Clearance Officer, United States
Department of Justice, Justice
Management Division, Policy and
Planning Staff, Patrick Henry Building,
Suite 1600, 601 D Street, NW.,
Washington, DC 20530.
Dated: August 23, 2006.
Lynn Bryant,
Department Clearance Officer, U.S.
Department of Justice.
[FR Doc. E6–14278 Filed 8–28–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–290P]
Controlled Substances: Proposed
Aggregate Production Quotas for 2007
Drug Enforcement
Administration (DEA), Justice.
ACTION: Notice of proposed year 2007
aggregate production quotas.
AGENCY:
SUMMARY: This notice proposes initial
year 2007 aggregate production quotas
for controlled substances in Schedules I
and II of the Controlled Substances Act
(CSA).
DATES: Comments or objections must be
received on or before September 19,
2006.
To ensure proper handling
of comments, please reference ‘‘Docket
No. DEA–290P’’ on all written and
electronic correspondence. Written
comments being sent via regular mail
should be sent to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, Washington, DC 20537,
ADDRESSES:
E:\FR\FM\29AUN1.SGM
29AUN1
Federal Register / Vol. 71, No. 167 / Tuesday, August 29, 2006 / Notices
Attention: DEA Federal Register
Representative/ODL. Written comments
sent via express mail should be sent to
DEA Headquarters, Attention: DEA
Federal Register Representative/ODL,
2401 Jefferson-Davis Highway,
Alexandria, VA 22301. Comments may
be directly sent to DEA electronically by
sending an electronic message to
dea.diversion.policy@usdoj.gov.
Comments may also be sent
electronically through https://
www.regulations.gov using the
electronic comment form provided on
that site. An electronic copy of this
document is also available at the https://
www.regulations.gov Web site. DEA will
accept attachments to electronic
comments in Microsoft Word,
WordPerfect, Adobe PDF, or Excel file
formats only. DEA will not accept any
file format other than those specifically
listed here.
FOR FURTHER INFORMATION CONTACT:
Christine A. Sannerud, Ph.D., Chief,
Drug and Chemical Evaluation Section,
Drug Enforcement Administration,
Washington, DC 20537, Telephone:
(202) 307–7183.
SUPPLEMENTARY INFORMATION: Section
306 of the CSA (21 U.S.C. 826) requires
that the Attorney General establish
aggregate production quotas for each
basic class of controlled substance listed
in Schedules I and II. This
responsibility has been delegated to the
Administrator of the DEA by Section
0.100 of Title 28 of the Code of Federal
Regulations. The Administrator, in turn,
has redelegated this function to the
Deputy Administrator, pursuant to
Section 0.104 of Title 28 of the Code of
Federal Regulations.
The proposed year 2007 aggregate
production quotas represent those
quantities of controlled substances that
may be produced in the United States in
2007 to provide adequate supplies of
each substance for: the estimated
medical, scientific, research, and
industrial needs of the United States;
lawful export requirements; and the
establishment and maintenance of
reserve stocks. These quotas do not
include imports of controlled
substances for use in industrial
processes.
In determining the proposed year
2007 aggregate production quotas, the
Deputy Administrator considered the
following factors: total actual 2005 and
estimated 2006 and 2007 net disposals
of each substance by all manufacturers;
estimates of 2006 year-end inventories
of each substance and of any substance
manufactured from it and trends in
accumulation of such inventories;
product development requirements of
51215
both bulk and finished dosage form
manufacturers; projected demand as
indicated by procurement quota
applications filed pursuant to Section
1303.12 of Title 21 of the Code of
Federal Regulations; and other pertinent
information.
Pursuant to Section 1303 of Title 21
of the Code of Federal Regulations, the
Deputy Administrator of the DEA will,
in early 2007, adjust aggregate
production quotas and individual
manufacturing quotas allocated for the
year based upon 2006 year-end
inventory and actual 2006 disposition
data supplied by quota recipients for
each basic class of Schedule I or II
controlled substance.
Therefore, under the authority vested
in the Attorney General by Section 306
of the CSA of 1970 (21 U.S.C. 826), and
delegated to the Administrator of the
DEA by Section 0.100 of Title 28 of the
Code of Federal Regulations, and
redelegated to the Deputy Administrator
pursuant to Section 0.104 of Title 28 of
the Code of Federal Regulations, the
Deputy Administrator hereby proposes
that the year 2007 aggregate production
quotas for the following controlled
substances, expressed in grams of
anhydrous acid or base, be established
as follows:
jlentini on PROD1PC65 with NOTICES
Basic class—schedule I
Proposed
year 2007
quotas
2,5–Dimethoxyamphetamine ...............................................................................................................................................................
2,5–Dimethoxy-4-ethylamphetamine (DOET) ......................................................................................................................................
2,5–Dimethoxy-4-(n)-propylthiophenethylamine (2C–T–7) ..................................................................................................................
3–Methylfentanyl ..................................................................................................................................................................................
3–Methylthiofentanyl ............................................................................................................................................................................
3,4–Methylenedioxyamphetamine (MDA) ............................................................................................................................................
3,4–Methylenedioxy-N-ethylamphetamine (MDEA) .............................................................................................................................
3,4–Methylenedioxymethamphetamine (MDMA) .................................................................................................................................
3,4,5–Trimethoxyamphetamine ...........................................................................................................................................................
4–Bromo-2,5-dimethoxyamphetamine (DOB) .....................................................................................................................................
4–Bromo-2,5-dimethoxyphenethylamine (2–CB) .................................................................................................................................
4–Methoxyamphetamine ......................................................................................................................................................................
4–Methylaminorex ................................................................................................................................................................................
4–Methyl-2,5-dimethoxyamphetamine (DOM) .....................................................................................................................................
5–Methoxy-3,4-methylenedioxyamphetamine .....................................................................................................................................
5–Methoxy-N,N-diisopropyltryptamine .................................................................................................................................................
Acetyl-alpha-methylfentanyl .................................................................................................................................................................
Acetyldihydrocodeine ...........................................................................................................................................................................
Acetylmethadol ....................................................................................................................................................................................
Allylprodine ..........................................................................................................................................................................................
Alphacetylmethadol ..............................................................................................................................................................................
Alpha-ethyltryptamine ..........................................................................................................................................................................
Alphameprodine ...................................................................................................................................................................................
Alphamethadol .....................................................................................................................................................................................
Alpha-methylfentanyl ...........................................................................................................................................................................
Alpha-methylthiofentanyl ......................................................................................................................................................................
Alpha-methyltryptamine .......................................................................................................................................................................
Aminorex ..............................................................................................................................................................................................
Benzylmorphine ...................................................................................................................................................................................
Betacetylmethadol ...............................................................................................................................................................................
Beta-hydroxy-3-methylfentanyl ............................................................................................................................................................
Beta-hydroxyfentanyl ...........................................................................................................................................................................
Betameprodine .....................................................................................................................................................................................
2,001,000
2
10
2
2
20
10
22
2
2
7
77
2
12
2
5
2
2
2
2
2
2
2
3
2
2
5
2
2
2
2
2
2
VerDate Aug<31>2005
17:07 Aug 28, 2006
Jkt 208001
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
E:\FR\FM\29AUN1.SGM
29AUN1
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
51216
Federal Register / Vol. 71, No. 167 / Tuesday, August 29, 2006 / Notices
Proposed
year 2007
quotas
Betamethadol .......................................................................................................................................................................................
Betaprodine ..........................................................................................................................................................................................
Bufotenine ............................................................................................................................................................................................
Cathinone .............................................................................................................................................................................................
Codeine-N-oxide ..................................................................................................................................................................................
Diethyltryptamine .................................................................................................................................................................................
Difenoxin ..............................................................................................................................................................................................
Dihydromorphine ..................................................................................................................................................................................
Dimethyltryptamine ..............................................................................................................................................................................
Gamma-hydroxybutyric acid ................................................................................................................................................................
Heroin ..................................................................................................................................................................................................
Hydromorphinol ....................................................................................................................................................................................
Hydroxypethidine .................................................................................................................................................................................
Lysergic acid diethylamide (LSD) ........................................................................................................................................................
Marihuana ............................................................................................................................................................................................
Mescaline .............................................................................................................................................................................................
Methaqualone ......................................................................................................................................................................................
Methcathinone .....................................................................................................................................................................................
Methyldihydromorphine ........................................................................................................................................................................
Morphine-N-oxide ................................................................................................................................................................................
N,N-Dimethylamphetamine ..................................................................................................................................................................
N-Ethylamphetamine ...........................................................................................................................................................................
N-Hydroxy-3,4-methylenedioxyamphetamine ......................................................................................................................................
Noracymethadol ...................................................................................................................................................................................
Norlevorphanol .....................................................................................................................................................................................
Normethadone .....................................................................................................................................................................................
Normorphine ........................................................................................................................................................................................
Para-fluorofentanyl ...............................................................................................................................................................................
Phenomorphan ....................................................................................................................................................................................
Pholcodine ...........................................................................................................................................................................................
Psilocybin .............................................................................................................................................................................................
Psilocyn ................................................................................................................................................................................................
Tetrahydrocannabinols ........................................................................................................................................................................
Thiofentanyl .........................................................................................................................................................................................
Trimeperidine .......................................................................................................................................................................................
2
2
8
3
302
2
50
2,549,000
3
8,000,000
5
3,000
2
61
4,500,000
2
10
4
2
310
7
2
2
2
52
2
16
2
2
2
7
7
312,500
2
2
Basic class—schedule II
Proposed year
2007 quotas
1–Phenylcyclohexylamine ....................................................................................................................................................................
Alfentanil ..............................................................................................................................................................................................
Alphaprodine ........................................................................................................................................................................................
Amobarbital ..........................................................................................................................................................................................
Amphetamine .......................................................................................................................................................................................
Cocaine ................................................................................................................................................................................................
Codeine (for sale) ................................................................................................................................................................................
Codeine (for conversion) .....................................................................................................................................................................
Dextropropoxyphene ............................................................................................................................................................................
Dihydrocodeine ....................................................................................................................................................................................
Diphenoxylate ......................................................................................................................................................................................
Ecgonine ..............................................................................................................................................................................................
Ethylmorphine ......................................................................................................................................................................................
Fentanyl ...............................................................................................................................................................................................
Glutethimide .........................................................................................................................................................................................
Hydrocodone (for sale) ........................................................................................................................................................................
Hydrocodone (for conversion) .............................................................................................................................................................
Hydromorphone ...................................................................................................................................................................................
Isomethadone ......................................................................................................................................................................................
Levo-alphacetylmethadol (LAAM) ........................................................................................................................................................
Levomethorphan ..................................................................................................................................................................................
Levorphanol .........................................................................................................................................................................................
Meperidine ...........................................................................................................................................................................................
Methadone (for sale) ...........................................................................................................................................................................
Methadone Intermediate ......................................................................................................................................................................
Methamphetamine ...............................................................................................................................................................................
jlentini on PROD1PC65 with NOTICES
Basic class—schedule I
2
5,000
2
2
17,000,000
286,000
39,605,000
55,000,000
167,365,000
2,200,000
828,000
83,000
2
1,428,000
2
41,252,000
1,500,000
3,300,000
2
6
5
6,000
9,753,000
25,000,000
26,000,000
3,130,000
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
[680,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 2405,000 grams for methamphetamine mostly for
conversion to a Schedule III product; and 45,000 grams for methamphetamine (for sale)]
Methylphenidate ...................................................................................................................................................................................
Morphine (for sale) ..............................................................................................................................................................................
Morphine (for conversion) ....................................................................................................................................................................
VerDate Aug<31>2005
17:07 Aug 28, 2006
Jkt 208001
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
E:\FR\FM\29AUN1.SGM
29AUN1
35,000,000 g
35,000,000 g
110,774,000 g
Federal Register / Vol. 71, No. 167 / Tuesday, August 29, 2006 / Notices
51217
Proposed year
2007 quotas
Nabilone ...............................................................................................................................................................................................
Noroxymorphone (for sale) ..................................................................................................................................................................
Noroxymorphone (for conversion) .......................................................................................................................................................
Opium ..................................................................................................................................................................................................
Oxycodone (for sale) ...........................................................................................................................................................................
Oxycodone (for conversion) ................................................................................................................................................................
Oxymorphone ......................................................................................................................................................................................
Pentobarbital ........................................................................................................................................................................................
Phencyclidine .......................................................................................................................................................................................
Phenmetrazine .....................................................................................................................................................................................
Racemethorphan .................................................................................................................................................................................
Remifentanil .........................................................................................................................................................................................
Secobarbital .........................................................................................................................................................................................
Sufentanil .............................................................................................................................................................................................
Thebaine ..............................................................................................................................................................................................
jlentini on PROD1PC65 with NOTICES
Basic class—schedule II
2
1,002
6,600,000
1,400,000
49,200,000
2,600,000
1,500,000
28,000,000
2,021
2
2
2,700
2
6,500
72,453,000
The Deputy Administrator further
proposes that aggregate production
quotas for all other Schedules I and II
controlled substances included in
Sections 1308.11 and 1308.12 of Title 21
of the Code of Federal Regulations be
established at zero.
All interested persons are invited to
submit their comments in writing or
electronically regarding this proposal
following the procedures in the
ADDRESSES section of this document. A
person may object to or comment on the
proposal relating to any of the abovementioned substances without filing
comments or objections regarding the
others. If a person believes that one or
more of these issues warrant a hearing,
the individual should so state and
summarize the reasons for this belief.
In the event that comments or
objections to this proposal raise one or
more issues which the Deputy
Administrator finds warrant a hearing,
the Deputy Administrator shall order a
public hearing by notice in the Federal
Register, summarizing the issues to be
heard and setting the time for the
hearing.
The Office of Management and Budget
has determined that notices of aggregate
production quotas are not subject to
centralized review under Executive
Order 12866.
This action does not preempt or
modify any provision of state law; nor
does it impose enforcement
responsibilities on any state; nor does it
diminish the power of any state to
enforce its own laws. Accordingly, this
action does not have federalism
implications warranting the application
of Executive Order 13132.
The Deputy Administrator hereby
certifies that this action will have no
significant impact upon small entities
whose interests must be considered
under the Regulatory Flexibility Act, 5
U.S.C. 601 et seq. The establishment of
aggregate production quotas for
VerDate Aug<31>2005
17:07 Aug 28, 2006
Jkt 208001
Schedules I and II controlled substances
is mandated by law and by international
treaty obligations. The quotas are
necessary to provide for the estimated
medical, scientific, research and
industrial needs of the United States, for
export requirements and the
establishment and maintenance of
reserve stocks. While aggregate
production quotas are of primary
importance to large manufacturers, their
impact upon small entities is neither
negative nor beneficial. Accordingly, the
Deputy Administrator has determined
that this action does not require a
regulatory flexibility analysis.
This action meets the applicable
standards set forth in Sections 3(a) and
3(b)(2) of Executive Order 12988 Civil
Justice Reform.
This action will not result in the
expenditure by State, local, and tribal
governments, in the aggregate, or by the
private sector, of $118,000,000 or more
in any one year, and will not
significantly or uniquely affect small
governments. Therefore, no actions were
deemed necessary under the provisions
of the Unfunded Mandates Reform Act
of 1995.
This action is not a major rule as
defined by Section 804 of the Small
Business Regulatory Enforcement
Fairness Act of 1996. This action will
not result in an annual effect on the
economy of $100,000,000 or more; a
major increase in costs or prices; or
significant adverse effects on
competition, employment, investment,
productivity, innovation, or on the
ability of United States-based
companies to compete with foreignbased companies in domestic and
export markets.
Dated: August 22, 2006.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. E6–14284 Filed 8–28–06; 8:45 am]
BILLING CODE 4410–09–P
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
DEPARTMENT OF LABOR
Employment and Training
Administration
[TA–W–59,772]
E.I. Dupont, Dupont Automotive
Systems Division, Troy, MI; Notice of
Termination of Investigation
Pursuant to Section 221 of the Trade
Act of 1974, as amended, an
investigation was initiated on July 25,
2006 in response to a petition filed by
a company official on behalf of workers
at E.I. DuPont, DuPont Automotive
Systems Division, Troy, Michigan. The
workers at the subject facility produced
automotive paints.
The petitioner has requested that the
petition be withdrawn. Consequently,
the investigation has been terminated.
Signed in Washington, DC, this 18th day of
August, 2006.
Richard Church,
Certifying Officer, Division of Trade
Adjustment Assistance.
[FR Doc. E6–14329 Filed 8–28–06; 8:45 am]
BILLING CODE 4510–30–P
DEPARTMENT OF LABOR
Employment and Training
Administration
[TA–W–56,672A]
Golden Northwest Aluminum, Inc.,
Northwest Aluminum Specialties
Company, Currently Known as
Northwest Aluminum Specialties, Inc.,
The Dalles, OR; Amended Certification
Regarding Eligibility To Apply for
Worker Adjustment Assistance and
Alternative Trade Adjustment
Assistance
In accordance with Section 223 of the
Trade Act of 1974 (19 U.S.C. 2273), and
Section 246 of the Trade Act of 1974 (26
E:\FR\FM\29AUN1.SGM
29AUN1
]]>Agencies
[Federal Register Volume 71, Number 167 (Tuesday, August 29, 2006)]
[Notices]
[Pages 51214-51217]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-14284]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-290P]
Controlled Substances: Proposed Aggregate Production Quotas for
2007
AGENCY: Drug Enforcement Administration (DEA), Justice.
ACTION: Notice of proposed year 2007 aggregate production quotas.
-----------------------------------------------------------------------
SUMMARY: This notice proposes initial year 2007 aggregate production
quotas for controlled substances in Schedules I and II of the
Controlled Substances Act (CSA).
DATES: Comments or objections must be received on or before September
19, 2006.
ADDRESSES: To ensure proper handling of comments, please reference
``Docket No. DEA-290P'' on all written and electronic correspondence.
Written comments being sent via regular mail should be sent to the
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration, Washington, DC 20537,
[[Page 51215]]
Attention: DEA Federal Register Representative/ODL. Written comments
sent via express mail should be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway,
Alexandria, VA 22301. Comments may be directly sent to DEA
electronically by sending an electronic message to
dea.diversion.policy@usdoj.gov. Comments may also be sent
electronically through https://www.regulations.gov using the electronic
comment form provided on that site. An electronic copy of this document
is also available at the https://www.regulations.gov Web site. DEA will
accept attachments to electronic comments in Microsoft Word,
WordPerfect, Adobe PDF, or Excel file formats only. DEA will not accept
any file format other than those specifically listed here.
FOR FURTHER INFORMATION CONTACT: Christine A. Sannerud, Ph.D., Chief,
Drug and Chemical Evaluation Section, Drug Enforcement Administration,
Washington, DC 20537, Telephone: (202) 307-7183.
SUPPLEMENTARY INFORMATION: Section 306 of the CSA (21 U.S.C. 826)
requires that the Attorney General establish aggregate production
quotas for each basic class of controlled substance listed in Schedules
I and II. This responsibility has been delegated to the Administrator
of the DEA by Section 0.100 of Title 28 of the Code of Federal
Regulations. The Administrator, in turn, has redelegated this function
to the Deputy Administrator, pursuant to Section 0.104 of Title 28 of
the Code of Federal Regulations.
The proposed year 2007 aggregate production quotas represent those
quantities of controlled substances that may be produced in the United
States in 2007 to provide adequate supplies of each substance for: the
estimated medical, scientific, research, and industrial needs of the
United States; lawful export requirements; and the establishment and
maintenance of reserve stocks. These quotas do not include imports of
controlled substances for use in industrial processes.
In determining the proposed year 2007 aggregate production quotas,
the Deputy Administrator considered the following factors: total actual
2005 and estimated 2006 and 2007 net disposals of each substance by all
manufacturers; estimates of 2006 year-end inventories of each substance
and of any substance manufactured from it and trends in accumulation of
such inventories; product development requirements of both bulk and
finished dosage form manufacturers; projected demand as indicated by
procurement quota applications filed pursuant to Section 1303.12 of
Title 21 of the Code of Federal Regulations; and other pertinent
information.
Pursuant to Section 1303 of Title 21 of the Code of Federal
Regulations, the Deputy Administrator of the DEA will, in early 2007,
adjust aggregate production quotas and individual manufacturing quotas
allocated for the year based upon 2006 year-end inventory and actual
2006 disposition data supplied by quota recipients for each basic class
of Schedule I or II controlled substance.
Therefore, under the authority vested in the Attorney General by
Section 306 of the CSA of 1970 (21 U.S.C. 826), and delegated to the
Administrator of the DEA by Section 0.100 of Title 28 of the Code of
Federal Regulations, and redelegated to the Deputy Administrator
pursuant to Section 0.104 of Title 28 of the Code of Federal
Regulations, the Deputy Administrator hereby proposes that the year
2007 aggregate production quotas for the following controlled
substances, expressed in grams of anhydrous acid or base, be
established as follows:
------------------------------------------------------------------------
Proposed year
Basic class--schedule I 2007 quotas
------------------------------------------------------------------------
2,5-Dimethoxyamphetamine................................ 2,001,000 g
2,5-Dimethoxy-4-ethylamphetamine (DOET)................. 2 g
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7)... 10 g
3-Methylfentanyl........................................ 2 g
3-Methylthiofentanyl.................................... 2 g
3,4-Methylenedioxyamphetamine (MDA)..................... 20 g
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)............ 10 g
3,4-Methylenedioxymethamphetamine (MDMA)................ 22 g
3,4,5-Trimethoxyamphetamine............................. 2 g
4-Bromo-2,5-dimethoxyamphetamine (DOB).................. 2 g
4-Bromo-2,5-dimethoxyphenethylamine (2-CB).............. 7 g
4-Methoxyamphetamine.................................... 77 g
4-Methylaminorex........................................ 2 g
4-Methyl-2,5-dimethoxyamphetamine (DOM)................. 12 g
5-Methoxy-3,4-methylenedioxyamphetamine................. 2 g
5-Methoxy-N,N-diisopropyltryptamine..................... 5 g
Acetyl-alpha-methylfentanyl............................. 2 g
Acetyldihydrocodeine.................................... 2 g
Acetylmethadol.......................................... 2 g
Allylprodine............................................ 2 g
Alphacetylmethadol...................................... 2 g
Alpha-ethyltryptamine................................... 2 g
Alphameprodine.......................................... 2 g
Alphamethadol........................................... 3 g
Alpha-methylfentanyl.................................... 2 g
Alpha-methylthiofentanyl................................ 2 g
Alpha-methyltryptamine.................................. 5 g
Aminorex................................................ 2 g
Benzylmorphine.......................................... 2 g
Betacetylmethadol....................................... 2 g
Beta-hydroxy-3-methylfentanyl........................... 2 g
Beta-hydroxyfentanyl.................................... 2 g
Betameprodine........................................... 2 g
[[Page 51216]]
Betamethadol............................................ 2 g
Betaprodine............................................. 2 g
Bufotenine.............................................. 8 g
Cathinone............................................... 3 g
Codeine-N-oxide......................................... 302 g
Diethyltryptamine....................................... 2 g
Difenoxin............................................... 50 g
Dihydromorphine......................................... 2,549,000 g
Dimethyltryptamine...................................... 3 g
Gamma-hydroxybutyric acid............................... 8,000,000 g
Heroin.................................................. 5 g
Hydromorphinol.......................................... 3,000 g
Hydroxypethidine........................................ 2 g
Lysergic acid diethylamide (LSD)........................ 61 g
Marihuana............................................... 4,500,000 g
Mescaline............................................... 2 g
Methaqualone............................................ 10 g
Methcathinone........................................... 4 g
Methyldihydromorphine................................... 2 g
Morphine-N-oxide........................................ 310 g
N,N-Dimethylamphetamine................................. 7 g
N-Ethylamphetamine...................................... 2 g
N-Hydroxy-3,4-methylenedioxyamphetamine................. 2 g
Noracymethadol.......................................... 2 g
Norlevorphanol.......................................... 52 g
Normethadone............................................ 2 g
Normorphine............................................. 16 g
Para-fluorofentanyl..................................... 2 g
Phenomorphan............................................ 2 g
Pholcodine.............................................. 2 g
Psilocybin.............................................. 7 g
Psilocyn................................................ 7 g
Tetrahydrocannabinols................................... 312,500 g
Thiofentanyl............................................ 2 g
Trimeperidine........................................... 2 g
------------------------------------------------------------------------
------------------------------------------------------------------------
Proposed year
Basic class--schedule II 2007 quotas
------------------------------------------------------------------------
1-Phenylcyclohexylamine................................. 2 g
Alfentanil.............................................. 5,000 g
Alphaprodine............................................ 2 g
Amobarbital............................................. 2 g
Amphetamine............................................. 17,000,000 g
Cocaine................................................. 286,000 g
Codeine (for sale)...................................... 39,605,000 g
Codeine (for conversion)................................ 55,000,000 g
Dextropropoxyphene...................................... 167,365,000 g
Dihydrocodeine.......................................... 2,200,000 g
Diphenoxylate........................................... 828,000 g
Ecgonine................................................ 83,000 g
Ethylmorphine........................................... 2 g
Fentanyl................................................ 1,428,000 g
Glutethimide............................................ 2 g
Hydrocodone (for sale).................................. 41,252,000 g
Hydrocodone (for conversion)............................ 1,500,000 g
Hydromorphone........................................... 3,300,000 g
Isomethadone............................................ 2 g
Levo-alphacetylmethadol (LAAM).......................... 6 g
Levomethorphan.......................................... 5 g
Levorphanol............................................. 6,000 g
Meperidine.............................................. 9,753,000 g
Methadone (for sale).................................... 25,000,000 g
Methadone Intermediate.................................. 26,000,000 g
Methamphetamine......................................... 3,130,000 g
------------------------------------------------------------------------
[680,000 grams of levo-desoxyephedrine for use in a non-controlled, non-
prescription product; 2405,000 grams for methamphetamine mostly for
conversion to a Schedule III product; and 45,000 grams for
methamphetamine (for sale)]
------------------------------------------------------------------------
Methylphenidate......................................... 35,000,000 g
Morphine (for sale)..................................... 35,000,000 g
Morphine (for conversion)............................... 110,774,000 g
[[Page 51217]]
Nabilone................................................ 2 g
Noroxymorphone (for sale)............................... 1,002 g
Noroxymorphone (for conversion)......................... 6,600,000 g
Opium................................................... 1,400,000 g
Oxycodone (for sale).................................... 49,200,000 g
Oxycodone (for conversion).............................. 2,600,000 g
Oxymorphone............................................. 1,500,000 g
Pentobarbital........................................... 28,000,000 g
Phencyclidine........................................... 2,021 g
Phenmetrazine........................................... 2 g
Racemethorphan.......................................... 2 g
Remifentanil............................................ 2,700 g
Secobarbital............................................ 2 g
Sufentanil.............................................. 6,500 g
Thebaine................................................ 72,453,000 g
------------------------------------------------------------------------
The Deputy Administrator further proposes that aggregate production
quotas for all other Schedules I and II controlled substances included
in Sections 1308.11 and 1308.12 of Title 21 of the Code of Federal
Regulations be established at zero.
All interested persons are invited to submit their comments in
writing or electronically regarding this proposal following the
procedures in the ADDRESSES section of this document. A person may
object to or comment on the proposal relating to any of the above-
mentioned substances without filing comments or objections regarding
the others. If a person believes that one or more of these issues
warrant a hearing, the individual should so state and summarize the
reasons for this belief.
In the event that comments or objections to this proposal raise one
or more issues which the Deputy Administrator finds warrant a hearing,
the Deputy Administrator shall order a public hearing by notice in the
Federal Register, summarizing the issues to be heard and setting the
time for the hearing.
The Office of Management and Budget has determined that notices of
aggregate production quotas are not subject to centralized review under
Executive Order 12866.
This action does not preempt or modify any provision of state law;
nor does it impose enforcement responsibilities on any state; nor does
it diminish the power of any state to enforce its own laws.
Accordingly, this action does not have federalism implications
warranting the application of Executive Order 13132.
The Deputy Administrator hereby certifies that this action will
have no significant impact upon small entities whose interests must be
considered under the Regulatory Flexibility Act, 5 U.S.C. 601 et seq.
The establishment of aggregate production quotas for Schedules I and II
controlled substances is mandated by law and by international treaty
obligations. The quotas are necessary to provide for the estimated
medical, scientific, research and industrial needs of the United
States, for export requirements and the establishment and maintenance
of reserve stocks. While aggregate production quotas are of primary
importance to large manufacturers, their impact upon small entities is
neither negative nor beneficial. Accordingly, the Deputy Administrator
has determined that this action does not require a regulatory
flexibility analysis.
This action meets the applicable standards set forth in Sections
3(a) and 3(b)(2) of Executive Order 12988 Civil Justice Reform.
This action will not result in the expenditure by State, local, and
tribal governments, in the aggregate, or by the private sector, of
$118,000,000 or more in any one year, and will not significantly or
uniquely affect small governments. Therefore, no actions were deemed
necessary under the provisions of the Unfunded Mandates Reform Act of
1995.
This action is not a major rule as defined by Section 804 of the
Small Business Regulatory Enforcement Fairness Act of 1996. This action
will not result in an annual effect on the economy of $100,000,000 or
more; a major increase in costs or prices; or significant adverse
effects on competition, employment, investment, productivity,
innovation, or on the ability of United States-based companies to
compete with foreign-based companies in domestic and export markets.
Dated: August 22, 2006.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. E6-14284 Filed 8-28-06; 8:45 am]
BILLING CODE 4410-09-P
